Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 4

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 4
---
 timing of potential regulatory designations, approvals and commercialization of product candidates; |

| • | potential litigation related to the Merger instituted against us or our directors; |

| • | our ability to prevent or minimize the effects of litigation and other contingencies; |

| • | our status as a preclinical and development-stage company and our expectation to incur losses in the future, and the possibility that we never achieve or maintain profitability; |

| • | uncertainties with respect to our ability to access future capital; |

| • | our ability to maximize the value of our pipeline of product candidates; |

| • | our unproven approach to therapeutic intervention; |

| • | our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals; |

2

TABLE OF CONTENTS

| • | our ability to continue to grow our manufacturing capabilities and resources; |

| • | our ability to manufacture our product candidates, which in some cases are manufactured on a patient-by-patient basis; |

| • | our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates; |

| • | our ability to maintain our existing or future collaborations or licenses and to seek new collaborations, licenses or partnerships; |

| • | the impact of resurgence of the COVID-19 pandemic on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions; |

| • | our ability to protect and enforce our intellectual property rights; |

| • | federal, state, and foreign regulatory requirements, including U.S. Food and Drug Administration, or FDA, regulation of our product candidates; |

| • | our ability to obtain and retain key executives and retain qualified personnel; and |

| • | developments relating to our competitors and our industry, including the impact of government regulation. |

The foregoing list may not contain all of the forward-looking statements made in this prospectus. These forward-looking statements are only predictions based on our current expectations and projections about future events and are subject to a number of risks, uncertainties and assumptions, including those described in “ Risk Factors” and elsewhere in this prospectus. Moreover, we operate in a competitive industry, and new risks emerge from time to time. It is not possible for the management of Cartesian to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we